Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a $6.79 billion market cap biopharmaceutical company whose stock has gained nearly 12% in the past week, recently sold 347 ...

Citi analyst David Lebowitz has maintained their bullish stance on MDGL stock, giving a Buy rating yesterday.Invest with Confidence: Follow ...

The transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted ...

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic about the company's sales results.

Madrigal Pharmaceuticals (MDGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yasmeen ...

Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

WEST CONSHOHOCKEN, PA—William John Sibold, the President and CEO of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), has sold shares of the company worth $531,020. The transaction involved the sale ...

Infinity Pharmaceuticals Inc. 0.00% $90.76 ...

Madrigal Pharmaceuticals announced its preliminary Q4 and full-year results. The company topped the official Wall Street estimates, but seems to have missed the so-called "whisper numbers." ...